[Insulin aspart(NN-X14)].
Insulin aspart is a novel rapid-acting human insulin analogue, which structure is almost identical to human insulin, except for the substitution of a single residue in the amino acid sequence of the insulin. The structure of insulin aspart leads to more rapid absorption than human insulin. As a result, insulin aspart provides significantly better postprandial glucose control than human insulin. As mealtime insulin in a basal-bolus regimen, insulin aspart gives stable 24-hour blood glucose control, with lower maximum glucose levels during daytime than with human insulin. The better daily glycaemic profile with insulin aspart gives the better long-term metabolic control estimated by HbA1C. The score of patients' satisfaction in DTSQ(Diabetes Treatment Satisfaction Questionnaire) was greater with insulin aspart treatment. The overall safety of insulin aspart is comparable to human insulin.
Namba
M
M
Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo Medical College.
D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000097:blood / Q000188:drug therapy; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000493:pharmacokinetics; D007279:Injections, Subcutaneous; D007328:Insulin / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000493:pharmacokinetics; D061267:Insulin Aspart; D017060:Patient Satisfaction
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D061267:Insulin Aspart